NCT01406327View on ClinicalTrials.gov

Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)

CompletedOBSERVATIONAL
Enrollment

900

Participants

Timeline

Start Date

December 14, 2010

Primary Completion Date

February 28, 2020

Study Completion Date

February 28, 2020

Conditions
Hypertension, Pulmonary
Interventions
DRUG

Ambrisentan

Ambrisentan

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01406327 - Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension) | Biotech Hunter | Biotech Hunter